Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results : (2) Arrow Down
Filter Results : (2) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (7)
    • Faculty Publications  (2)

    Show Results For

    • All HBS Web  (7)
      • Faculty Publications  (2)

      Therapeutic Radiation Remove Therapeutic Radiation →

      Page 1 of 2 Results

      Are you looking for?

      → Search All HBS Web
      • September 2012
      • Supplement

      Intraoperative Radiotherapy for Breast Cancer (B)

      By: Willy Shih
      The intraoperative radiotherapy (IORT) business at Carl Zeiss Meditec had struggled with growth since the time of the (A) case. Though the unit had grown revenues in excess of 50% and had exceeded its EBIT target, it faced several key strategic choices. Should it...  View Details
      Keywords: Radiotherapy; Breast Cancer; Brachytherapy; Therapeutic Radiation; Oncology; Oncology Treatment Systems; Elekta AB; Varian Medical Systems; Xoft; Electronic Brachytherapy; Intraoperative Radiotherapy; Disruptive Innovation; Health Care and Treatment; Entrepreneurship; Technological Innovation; Growth and Development Strategy; Health Industry; Germany
      Citation
      Purchase
      Related
      Shih, Willy. "Intraoperative Radiotherapy for Breast Cancer (B)." Harvard Business School Supplement 613-040, September 2012.
      • January 2001 (Revised July 2003)
      • Case

      Pharmacyclics: Financing Research & Development

      By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
      Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...  View Details
      Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Pharmaceutical Industry; Health Industry
      Citation
      Educators
      Purchase
      Related
      Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
      • 1

      Are you looking for?

      → Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College